Griffith University Develops Drug Reversing Sepsis Damage

Researchers at Australia's Griffith University report Phase II human trial results in China for STC3141, a carbohydrate-based infusion that calms immune overreaction and reduced sepsis severity. The team plans Phase III effectiveness trials and hopes for market approval within a few years if results hold. Northeastern University also reported an AI model predicting septic shock with over 99% accuracy.